TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

CARNEXIV

CARBAMAZEPINE
Approved 2016-10-07
Jump to: Indications Approvals Trials Competitors Safety Patents
1
Indication
--
Phase 3 Trials
9
Years on Market

Details

Status
Discontinued
First Approved
2016-10-07
Routes
INTRAVENOUS
Dosage Forms
SOLUTION

Companies

LUNDBECK PHARMS LLC
Active Ingredient: CARBAMAZEPINE

CARNEXIV Approval History

Loading approval history...

What CARNEXIV Treats

1 FDA approvals

Originally approved for its first indication in 2016 .

  • Other (1)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

CARNEXIV FDA Label Details

Pro

CARNEXIV Patents & Exclusivity

Latest Patent: Jan 2040

Patents (9 active)

US11529357 Expires Jan 31, 2040
US9493582 Expires Feb 27, 2033
US7635773 Expires Mar 13, 2029
US9750822 Expires Mar 13, 2029
US8410077 Expires Mar 13, 2029
US9629797 Expires Nov 10, 2028
US9770407 Expires Nov 10, 2028
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: NDA206030 → Patents: FDA Orange Book → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.